Elena Myasoedova1,2, Sherine E Gabriel3,4, Eric L Matteson3,4, John M Davis3,4, Terry M Therneau3,4, Cynthia S Crowson3,4. 1. From the Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. myasoedova.elena@mayo.edu. 2. E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science; C.S. Crowson, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; E.L. Matteson, MD MPH, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, and Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science; T.M. Therneau, PhD, Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; S.E. Gabriel, MD, MSc, Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, and Rutgers Robert Wood Johnson Medical School. myasoedova.elena@mayo.edu. 3. From the Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. 4. E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science; C.S. Crowson, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; E.L. Matteson, MD MPH, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, and Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; J.M. Davis III, MD, MS, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science; T.M. Therneau, PhD, Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science; S.E. Gabriel, MD, MSc, Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, and Rutgers Robert Wood Johnson Medical School.
Abstract
OBJECTIVE: To assess trends in cardiovascular (CV) mortality in patients with incident rheumatoid arthritis (RA) in 2000-07 versus the previous decades, compared with non-RA subjects. METHODS: The study population consisted of Olmsted County, Minnesota, USA residents with incident RA (age ≥ 18 yrs, 1987 American College of Rheumatology criteria was met in 1980-2007) and non-RA subjects from the same underlying population with similar age, sex, and calendar year of index. All subjects were followed until death, migration, or December 31, 2014. Followup was truncated for comparability. Aalen-Johansen methods were used to estimate CV mortality rates, adjusting for competing risk of other causes. Cox proportional hazards models were used to compare CV mortality by decade. RESULTS: The study included 813 patients with RA and 813 non-RA subjects (mean age 55.9 yrs; 68% women for both groups). Patients with incident RA in 2000-07 had markedly lower 10-year overall CV mortality (2.7%, 95% CI 0.6-4.9%) and coronary heart disease (CHD) mortality (1.1%, 95% CI 0.0-2.7%) than patients diagnosed in 1990-99 (7.1%, 95% CI 3.9-10.1% and 4.5%, 95% CI 1.9-7.1%, respectively; HR for overall CV death: 0.43, 95% CI 0.19-0.94; CHD death: HR 0.21, 95% CI 0.05-0.95). This improvement in CV mortality persisted after accounting for CV risk factors. Ten-year overall CV mortality and CHD mortality in 2000-07 RA incidence cohort was similar to non-RA subjects (p = 0.95 and p = 0.79, respectively). CONCLUSION: Our findings suggest significantly improved overall CV mortality, particularly CHD mortality, in patients with RA in recent years. Further studies are needed to examine the reasons for this improvement.
OBJECTIVE: To assess trends in cardiovascular (CV) mortality in patients with incident rheumatoid arthritis (RA) in 2000-07 versus the previous decades, compared with non-RA subjects. METHODS: The study population consisted of Olmsted County, Minnesota, USA residents with incident RA (age ≥ 18 yrs, 1987 American College of Rheumatology criteria was met in 1980-2007) and non-RA subjects from the same underlying population with similar age, sex, and calendar year of index. All subjects were followed until death, migration, or December 31, 2014. Followup was truncated for comparability. Aalen-Johansen methods were used to estimate CV mortality rates, adjusting for competing risk of other causes. Cox proportional hazards models were used to compare CV mortality by decade. RESULTS: The study included 813 patients with RA and 813 non-RA subjects (mean age 55.9 yrs; 68% women for both groups). Patients with incident RA in 2000-07 had markedly lower 10-year overall CV mortality (2.7%, 95% CI 0.6-4.9%) and coronary heart disease (CHD) mortality (1.1%, 95% CI 0.0-2.7%) than patients diagnosed in 1990-99 (7.1%, 95% CI 3.9-10.1% and 4.5%, 95% CI 1.9-7.1%, respectively; HR for overall CV death: 0.43, 95% CI 0.19-0.94; CHD death: HR 0.21, 95% CI 0.05-0.95). This improvement in CV mortality persisted after accounting for CV risk factors. Ten-year overall CV mortality and CHD mortality in 2000-07 RA incidence cohort was similar to non-RA subjects (p = 0.95 and p = 0.79, respectively). CONCLUSION: Our findings suggest significantly improved overall CV mortality, particularly CHD mortality, in patients with RA in recent years. Further studies are needed to examine the reasons for this improvement.
Authors: Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde Journal: Ann Rheum Dis Date: 2010-03-09 Impact factor: 19.103
Authors: Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde Journal: Ann Rheum Dis Date: 2015-05-12 Impact factor: 19.103
Authors: Antonio Naranjo; Tuulikki Sokka; Miguel A Descalzo; Jaime Calvo-Alén; Kim Hørslev-Petersen; Reijo K Luukkainen; Bernard Combe; Gerd R Burmester; Joe Devlin; Gianfranco Ferraccioli; Alessia Morelli; Monique Hoekstra; Maria Majdan; Stefan Sadkiewicz; Miguel Belmonte; Ann-Carin Holmqvist; Ernest Choy; Recep Tunc; Aleksander Dimic; Martin Bergman; Sergio Toloza; Theodore Pincus Journal: Arthritis Res Ther Date: 2008-03-06 Impact factor: 5.156
Authors: Mohammad Movahedi; Ruth Costello; Mark Lunt; Stephen Richard Pye; Jamie Christopher Sergeant; William Gregory Dixon Journal: Eur J Epidemiol Date: 2016-06-02 Impact factor: 8.082
Authors: Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson Journal: J Rheumatol Date: 2017-04-01 Impact factor: 4.666
Authors: Bryant R England; Harlan Sayles; Kaleb Michaud; Geoffrey M Thiele; Jill A Poole; Liron Caplan; Brian C Sauer; Grant W Cannon; Andreas Reimold; Gail S Kerr; Joshua F Baker; Ted R Mikuls Journal: Clin Rheumatol Date: 2018-10-02 Impact factor: 2.980
Authors: Gustavo Nogueira Schincariol Vicente; Ivânio Alves Pereira; Gláucio Ricardo Werner de Castro; Licia Maria Henrique da Mota; Ana Paula Carnieletto; Dhara Giovanna Santin de Souza; Fabiana Oenning da Gama; Ana Beatriz Vargas Santos; Cleandro Pires de Albuquerque; Manoel Barros Bértolo; Paulo Louzada Júnior; Rina Dalva Neubarth Giorgi; Sebastião Cezar Radominski; Maria Fernanda Brandão Resende Guimarães; Karina Rossi Bonfiglioli; Maria de Fátima Lobato da Cunha Sauma; Claiton Viegas Brenol; Geraldo da Rocha Castelar Pinheiro Journal: Adv Rheumatol Date: 2021-06-25